Furthermore, the use of GLI inhibitors in combination with PARP inhibitors showed improvement in progression-free survival compared to PARP inhibitors alone in breast cancer cases, which highlighted the role of GLI signaling in conferring resistance to other treatments [65]. The gene discussed is GLI1; the disease is breast carcinoma.